Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60. See comments.PubMedCrossRefGoogle Scholar
Centers for Disease Control and Prevention. Update: trends in AIDS incidence—United States, 1996. MMWR. 1997;46:861–7.Google Scholar
Centers for Disease Control and Prevention. HIV AIDS Surveillance Report. December 1998. Washington, DC: US Department of Health and Human Services; 1999.Google Scholar
Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395–401.PubMedCrossRefGoogle Scholar
Johnson PA, Lee TH, Cook EF, Rouan GW, Goldman L. Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med. 1993;118:593–601.PubMedGoogle Scholar
Maynard C, Fisher LD, Passamani ER, Pullum T. Blacks in the coronary artery surgery study (CASS): race and clinical decision making. Am J Public Health. 1986;76:1446–8.PubMedGoogle Scholar
Todd KH. Pain assessment and ethnicity. Ann Emerg Med. 1996;27:421–3.PubMedCrossRefGoogle Scholar
Moore RD, Bone LR, Geller G, Mamon JA, Stokes EJ, Levine DM. Prevalence, detection, and treatment of alcoholism in hospitalized patients. JAMA. 1989;261:403–7.PubMedCrossRefGoogle Scholar
Powe NR, Griffiths RI, de Lissovoy G, et al. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA. 1992;268:1434–40.PubMedCrossRefGoogle Scholar
Diehr P, Yergan J, Chu J, et al. Treatment modality and quality differences for black and white breast-cancer patients treated in community hospitals. Med Care. 1989;27:942–58.PubMedCrossRefGoogle Scholar
Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763–8.PubMedCrossRefGoogle Scholar
Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–9.PubMedCrossRefGoogle Scholar
Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–6.PubMedCrossRefGoogle Scholar
Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955–6. Letter.PubMedCrossRefGoogle Scholar
Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy. The Netherlands, Canada and Australia Study. JAMA. 1998;279:930–7.PubMedCrossRefGoogle Scholar
Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977–83.PubMedCrossRefGoogle Scholar
Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307–11.PubMedCrossRefGoogle Scholar
Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis. 1994;169:411–5.PubMedGoogle Scholar
Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis. 1997;175:1502–6.PubMedGoogle Scholar
Donovan R, Berrey M, Corey L, Mayers D. Prevalence of Protease Inhibitor and Reverse Transcriptase Inhibitor Resistance Mutations in Recent HIV-1 Seroconverters in Seattle. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
Boden D, Hurley A, Zhang L, et al. Prevalence of HIV-1 drug resistance mutations in newly infected individuals remains stable over a 3 year period. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
Ziegelstein RC, Bush DE, Fauerbach JA. Depression, adherence behavior, and coronary disease outcomes. Arch Intern Med. 1998;158:808–9. Letter.PubMedCrossRefGoogle Scholar
Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88–90.PubMedCrossRefGoogle Scholar
Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med. 1998;24:35–9.PubMedCrossRefGoogle Scholar
Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–3.PubMedGoogle Scholar
Cochrane GM. Compliance and outcomes in patients with asthma. Drugs. 1996;52:12–9.PubMedGoogle Scholar
Everett KD, Brantley PJ, Sletten C, Jones GN, McKnight GT. The relation of stress and depression to interdialytic weight gain in hemodialysis patients. Behav Med. 1995;21:25–30.PubMedCrossRefGoogle Scholar
Sensky T, Leger C, Gilmour S. Psychosocial and cognitive factors associated with adherence to dietary and fluid restriction regimens by people on chronic haemodialysis. Psychother Psychosomat. 1996;65:36–42.CrossRefGoogle Scholar
Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261–9.PubMedCrossRefGoogle Scholar
Patterson D, Swindells S, Mohr J, et al. How Much Adherence is Enough? A Prospective Study of Adherence to Protease Inhibitor Therapy Using MEMSCaps. Presented at the 6th Conference on Retrovirus and Opportunistic Infections, Chicago, Ill, 1999.
Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996;22:475–87.PubMedGoogle Scholar
Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med. 1997;102:164–70.PubMedCrossRefGoogle Scholar
Caminero JA, Pavon JM, Rodriguez de Castro F, et al. Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax. 1996;51:1130–3.PubMedCrossRefGoogle Scholar
Marco A, Cayl JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J. 1998;12:967–71.PubMedCrossRefGoogle Scholar
Tulsky J, Pilote L, Hahn J, Charlebois E, Chesney M, Moss AR. Adherence to TB prevention in the homeless. Presented at the American Thoracic Society Meeting, Chicago, Ill, 1999.
Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev. 1996;8:58–71.PubMedGoogle Scholar
Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495–502.PubMedCrossRefGoogle Scholar
Singh N, Berman S, Swindells S, et al. Adherence to antiretroviral therapy in HIV infected patients: impact of demographic, psychosocial, and medical regimen related variables. Presented at the International Disease Society of America annual meeting, Denver, Colo, 1998.
Haubrich R, Little S, Dube M, et al. Self-reported treatment adherence and drug/alcohol use are associated with virologic outcomes in CCTG 570: a clinical strategy trial of HIV antiretroviral monitoring. Presented at the 12th World AIDS Conference, Geneva, Switzerland, 1998.
Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485–8.PubMedCrossRefGoogle Scholar
Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969;280:1372–5.PubMedCrossRefGoogle Scholar
Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat. 1999;16:129–35.PubMedCrossRefGoogle Scholar
Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM, Tusel DJ, Hall SM. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998;66:832–7.PubMedCrossRefGoogle Scholar
Siqueland L, Crits-Christoph P, Frank A, et al. Predictors of dropout from psychosocial treatment of cocaine dependence. Drug Alcohol Depend. 1998;52:1–13.PubMedCrossRefGoogle Scholar
Cantwell B, McBride AJ. Self detoxication by amphetamine dependent patients: a pilot study. Drug Alcohol Depend. 1998;49:157–63.PubMedCrossRefGoogle Scholar
Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend. 1997;46:105–13.PubMedCrossRefGoogle Scholar
Cameron DW H-CM, Kravick S, et al. The advanced HIV Ritonavir Study Group: prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with Ritonavir update. Presented at the 11th International Conference of AIDS. Vancouver, Canada, 1996.
Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278:63–5.PubMedCrossRefGoogle Scholar
Gulick R, Mellors J, Havlir D, et al. Treatment with Indinavir (IDV), Zidovudine (ZDV), and Lamivudine (3TC): three-year follow-up. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
Rosenberg E. Preserving HIV-1 specific T-cell help: will it prevent progression? Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill. 1999.
Autran B. Effects of antiretroviral therapy on immune reconstitution. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J. 1980;123:119–22.PubMedGoogle Scholar